NCT03422302 Continuous Positive Airway Pressure Device or Deep Inspiration Breath Hold in Reducing Tumor Motion in Patients Undergoing Stereotactic Body Radiation Therapy for Lung Cancer
| NCT ID | NCT03422302 |
| Status | Recruiting |
| Phase | — |
| Sponsor | M.D. Anderson Cancer Center |
| Condition | Lung Carcinoma |
| Study Type | INTERVENTIONAL |
| Enrollment | 30 participants |
| Start Date | 2018-03-16 |
| Primary Completion | 2028-05-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 30 participants in total. It began in 2018-03-16 with a primary completion date of 2028-05-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This pilot phase I/II trial studies how well a continuous positive airway pressure device or deep inspiration breath hold works in reducing tumor movement in patients undergoing stereotactic body radiation therapy (SBRT) for lung cancer. The continuous positive airway pressure device works by blowing air into the lungs while patients wear a face mask or nozzle to help expand their airways and lungs. Deep inspiration breath hold is a standard technique that uses active breath-holding to restrict movement of the body. Using a continuous positive airway pressure device may work better than deep inspiration breath hold in lowering the amount of tumor movement during stereotactic radiation body therapy.
Eligibility Criteria
Inclusion Criteria: * The patient will receive stereotactic body radiotherapy in the Thoracic Radiation Oncolcogy Service at MD Anderson. Exclusion Criteria: * The patient has a contra-indication for using a CPAP device. * The patient has not signed a study-specific informed consent for this study. * The patient is uncooperative. * The patient has reduced consciousness. * The patient has sustained trauma or burns to the face. * The patient has undergone any facial, esophageal, gastric or sinus surgery within the last 3 months. * The patient has idiopathic pulmonary fibrosis (IPF) as documented in their medical history. * Adults who are unable to consent, individuals who are not yet adults, pregnant women and prisoners will be excluded from this study.
Contact & Investigator
Julianne M Pollard
PRINCIPAL INVESTIGATOR
M.D. Anderson Cancer Center
Frequently Asked Questions
Who can join the NCT03422302 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Lung Carcinoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT03422302 currently recruiting?
Yes, NCT03422302 is actively recruiting participants. Contact the research team at JMPollard@mdanderson.org for enrollment information.
Where is the NCT03422302 trial being conducted?
This trial is being conducted at Houston, United States.
Who is sponsoring the NCT03422302 clinical trial?
NCT03422302 is sponsored by M.D. Anderson Cancer Center. The principal investigator is Julianne M Pollard at M.D. Anderson Cancer Center. The trial plans to enroll 30 participants.